ILT3/CD85k/LILRB4 Antibody (U.Texas patent anti-LILRB4) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28106PCP
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Recombinant Monoclonal Human IgG Clone # U.Texas patent anti-LILRB4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
LILRB4 / ILT3 / CD85k
Clonality
Monoclonal
Host
Human
Isotype
IgG
Applications for ILT3/CD85k/LILRB4 Antibody (U.Texas patent anti-LILRB4) [PerCP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: LILRB4/CD85k/ILT3
Long Name
Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 4
Alternate Names
CD85k, HM18, ILT3, LIR5
Gene Symbol
LILRB4
Additional LILRB4/CD85k/ILT3 Products
Product Documents for ILT3/CD85k/LILRB4 Antibody (U.Texas patent anti-LILRB4) [PerCP]
Product Specific Notices for ILT3/CD85k/LILRB4 Antibody (U.Texas patent anti-LILRB4) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...